- Home
- GLUE vs NNOX Comparison
GLUE vs NNOX Comparison
Compare GLUE & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- NNOX
- Stock Information
- Founded
- GLUE 2019
- NNOX 2011
- Country
- GLUE United States
- NNOX Israel
- Employees
- GLUE N/A
- NNOX N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- NNOX Medical Electronics
- Sector
- GLUE Health Care
- NNOX Health Care
- Exchange
- GLUE Nasdaq
- NNOX Nasdaq
- Market Cap
- GLUE 351.2M
- NNOX 248.7M
- IPO Year
- GLUE 2021
- NNOX 2020
- Fundamental
- Price
- GLUE $4.80
- NNOX $3.85
- Analyst Decision
- GLUE Buy
- NNOX Strong Buy
- Analyst Count
- GLUE 2
- NNOX 2
- Target Price
- GLUE $13.50
- NNOX $8.50
- AVG Volume (30 Days)
- GLUE 369.2K
- NNOX 1.3M
- Earning Date
- GLUE 08-07-2025
- NNOX 08-12-2025
- Dividend Yield
- GLUE N/A
- NNOX N/A
- EPS Growth
- GLUE N/A
- NNOX N/A
- EPS
- GLUE 0.29
- NNOX N/A
- Revenue
- GLUE $177,986,000.00
- NNOX $11,886,000.00
- Revenue This Year
- GLUE $83.76
- NNOX $24.12
- Revenue Next Year
- GLUE N/A
- NNOX $160.56
- P/E Ratio
- GLUE $16.32
- NNOX N/A
- Revenue Growth
- GLUE 2990.57
- NNOX 17.36
- 52 Week Low
- GLUE $3.50
- NNOX $3.75
- 52 Week High
- GLUE $12.40
- NNOX $11.00
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- NNOX 32.78
- Support Level
- GLUE $4.54
- NNOX $3.88
- Resistance Level
- GLUE $4.93
- NNOX $4.16
- Average True Range (ATR)
- GLUE 0.21
- NNOX 0.19
- MACD
- GLUE 0.06
- NNOX -0.02
- Stochastic Oscillator
- GLUE 81.43
- NNOX 8.44
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.